Pennant Group Earnings Call Highlights Strong Growth

Pennant Group Inc ((PNTG)) has held its Q4 earnings call. Read on for the main highlights of the call.

Pennant Group Inc.’s latest earnings call struck an upbeat tone, underscoring outsized revenue and earnings growth in 2025, strong same-store trends, and standout clinical quality across its portfolio. Management acknowledged integration and reimbursement headwinds tied to recent large acquisitions, but emphasized a solid balance sheet and a disciplined plan that leaves investors focused more on upside than near-term noise.

Strong Full-Year Financial Performance

Pennant delivered a powerful 2025, with consolidated revenue climbing 36.3% to $947.7 million and adjusted EBITDA rising 36% to $72.5 million. Adjusted EPS reached $1.18, edging above the midpoint of guidance and signaling that the company is converting its rapid top-line expansion into bottom-line gains despite ongoing integration work.

Robust Fourth Quarter Home Health & Hospice Growth

Home health and hospice drove a standout fourth quarter, with revenue up 64.3% year over year to $233.3 million and adjusted EBITDA up 58.2% to $33.7 million. Admissions surged 81.3% overall and 87.5% for Medicare, while same-store Medicare admissions and revenue per episode rose, showing both acquisition and organic growth are firing.

High Clinical Quality Metrics

Management highlighted industry-leading clinical quality, a key differentiator as payors focus more on outcomes and value. The average CMS home health star rating rose to 4.2 versus the national 3.0, and hospice quality scores approached perfection, with select agencies such as Columbia River posting lower preventable hospitalization rates than national norms.

Accelerating Hospice Performance

Hospice continues to be a major growth engine, with average daily census in Q4 jumping 46.9% year over year to 5,060 patients. Same-store metrics were also strong, as census grew 8.4%, admissions rose 6.6%, and Medicare revenue per day increased 5.9%, indicating Pennant is deepening its presence rather than relying solely on bought growth.

Senior Living Momentum

The senior living segment showed renewed momentum, delivering 22.3% revenue growth in 2025 to $215 million and a 46% lift in Q4 adjusted EBITDA to $6.1 million. Occupancy improved both across all communities and in same-store locations, while revenue per occupied room rose 5.6%, suggesting pricing power alongside volume recovery.

Strategic M&A Execution and Scale Expansion

Pennant continued to scale aggressively, closing the integration of Signature Healthcare at Home and completing its largest-ever deal, adding more than 50 locations from UnitedHealth and Amedisys. Two senior living acquisitions in the quarter further expanded both operations and real estate, reinforcing a strategy of disciplined, accretive consolidation across care settings.

Conservative, Growth-Oriented 2026 Guidance

Management issued 2026 guidance that points to another year of double-digit growth, while building in cushion for integration risk and reimbursement pressure.

Healthy Balance Sheet and Cash Flow Outlook

The company expanded its credit facility to $350 million, including a $100 million term loan, which helped fund the $147.2 million UnitedHealth acquisition while keeping net leverage at a modest 1.7 times adjusted EBITDA. Operating cash flow reached $21 million in Q4 and $48.3 million year to date, with 2026 cash generation expected to comfortably cover capital spending and support further investment.

Integration Risk and Near-Term Choppiness

With over 50 acquired locations slated for phased transition through late 2026, management warned of operational choppiness during the first three quarters as systems, branding, and support structures are realigned. Guidance is deliberately conservative to reflect the potential for short-term inefficiencies, as Pennant works to bring these sites up to corporate standards.

Reimbursement Headwinds in Home Health

The home health segment faces ongoing reimbursement pressure, with management now planning around a roughly 1.3% rate cut instead of a steeper decline they had initially modeled. While they are rolling out margin initiatives to offset this drag, execution will be critical to maintain profitability as regulatory and payor dynamics remain fluid.

Transition Services and One-Time Costs

The UnitedHealth and Amedisys transaction comes with a transition services agreement and other one-time expenses that will temporarily distort cash collections and earnings. Although many of these acquisition-related and implementation costs are excluded from formal guidance, investors should expect some volatility in reported results as these non-recurring items flow through.

Increased Corporate and Integration Expense

Scaling the platform has also pushed corporate overhead higher, with G&A modeled at about 6.4% to 6.5% of revenue in 2026 as Pennant builds the infrastructure to support new locations. Additional integration teams and shared services are raising short-term costs, but management argues this investment is necessary to ensure a smooth transition and long-term operating leverage.

Some Acquired Locations Require Turnaround

The recent acquisitions include a mix of high-performing and underperforming assets, and several locations will need meaningful operational improvement before they contribute at Pennant’s typical margins. This turnaround work adds to the integration burden in the near term, but also creates upside if the company can successfully apply its playbook to lift these sites closer to its best-in-class operators.

Limited Cash on Hand Relative to M&A Activity

Pennant ended the year with $17 million in cash on hand, a modest figure relative to its recent deal activity, which underscores a greater reliance on credit facilities and debt. Even so, leverage remains comfortably below covenant limits, suggesting room for selective future deals if management maintains discipline and cash flow strengthens as planned.

Guidance Points to Continued Growth Amid Integration

For 2026, Pennant guided to revenue between $1.13 billion and $1.17 billion and adjusted EBITDA of $88.5 million to $94.1 million, implying mid‑20% growth at the midpoint for both the top and bottom line. Management expects quarterly EPS to ramp as newly acquired locations transition, with embedded assumptions for solid same-store growth, modest occupancy gains, and controlled G&A, while excluding unannounced M&A and one-time costs.

Pennant’s call painted a picture of a company in high-growth mode, leveraging scale and clinical quality to expand across home health, hospice, and senior living while carefully managing balance-sheet risk. Near-term volatility from integration, reimbursement, and elevated corporate expense is real, but the tone of management and the numbers behind the guidance suggest that, for now, the tailwinds outweigh the turbulence for long-term investors.